HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanner, C. M. Articles by Klawans, H. L. Search for Related Content PubMed PubMed Citation Articles by Tanner, C. M. Articles by Klawans, H. L.

Pergolide mesylate and idiopathic Parkinson disease

Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL.

We studied the effects of pergolide mesylate in an open trial of 23 patients with idiopathic Parkinson disease (PD). All had suffered from loss of efficacy or dose-limiting side effects on current antiparkinsonian regimens. On pergolide therapy, improvement, which was maintained for 6 months, was noted in some parkinsonian features in all 23 patients. All patients suffering from on-off phenomenon were helped by pergolide. Significant side effects were not encountered. Pergolide is useful in the treatment of PD.

Address correspondence and reprint requests to Dr. Tanner, Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison, Chicago, IL 60612.

This work was supported in part by grants from the United Parkinson Foundation, Boothroyd Foundation, Chicago, IL, and Eli Lilly Company, Indianapolis, IN. Dr. Goetz is the recipient of a NINCDS Teacher Investigator Award.

These data were presented in part at the American Academy of Neurology meeting, Toronto, Ontario, Canada, 1981.

Accepted for publication April 1, 1982.

This article has been cited by other articles:

				N. C. Reynolds Jr and G. K. Montgomery Factor Analysis of Parkinson's Impairment: An Evaluation of the Final Common Pathway Arch Neurol, October 1, 1987; 44(10): 1013 - 1016. [Abstract] [PDF]